Efficacy of a Wearable Noninvasive Neuromodulation Device
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI. The study hypotheses: * The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment. * The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.
Sponsor: University of Michigan
You may qualify if…
- ✓ Traumatic or non-traumatic spinal cord injury (SCI)
- ✓ SCI level above the twelfth thoracic vertebra (T12)
- ✓ SCI classified as Sensory Incomplete (AIS B), C, or D
- ✓ Post-SCI time ≥ 6 months;
- ✓ Neurogenic bowel dysfunction (NBD) as a result of SCI
- ✓ Willing to sign the informed consent form
You may not qualify if…
- ✕ Significant cognitive impairment, impeding the ability to provide informed consent or complete the questionnaire
- ✕ Prior gastrointestinal surgeries other than uncomplicated appendectomies, cholecystectomy or cesarean sections
- ✕ Known diagnosis of diabetes mellitus
- ✕ Known current or past severe significant psychiatric disorder
- ✕ Known current substance abuse
- ✕ Implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)
- ✕ Taking opioid medications on a regular daily basis
- ✕ Currently pregnant or actively planning a pregnancy
Where it's recruiting
Ann Arbor
Source: ClinicalTrials.gov · NCT07171489 · last updated 2026-07-06